GYNE-LOTRIMIN 3 COMBINATION PACK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GYNE-LOTRIMIN 3 COMBINATION PACK (GYNE-LOTRIMIN 3 COMBINATION PACK).
Clotrimazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability. The combination pack includes an insert for vaginal use and a topical cream for external use.
| Metabolism | Hepatic metabolism to inactive metabolites, primarily via oxidation and glucuronidation. Vaginal absorption minimal; systemic exposure low. |
| Excretion | Clotrimazole: ~0.03% of topical dose excreted renally as metabolites; majority eliminated in feces via biliary excretion. Vaginal administration: minimal systemic absorption (<3%), with absorbed drug primarily metabolized hepatically and excreted in bile/feces. |
| Half-life | Terminal half-life of absorbed clotrimazole is approximately 3.5-6 hours; clinically, topical application maintains local concentrations without reliance on systemic half-life. |
| Protein binding | Clotrimazole is ~90% bound to plasma proteins (albumin and alpha-1-acid glycoprotein) for the small fraction that enters systemic circulation. |
| Volume of Distribution | Apparent Vd is not clinically meaningful due to negligible systemic absorption. With intravenous data (not used clinically), Vd is ~2.1 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Vaginal administration: systemic bioavailability <3% (range 0.5-3%) due to minimal absorption through vaginal mucosa. Topical cream: negligible systemic absorption (<0.5%). |
| Onset of Action | Vaginal cream/tablet: symptom relief begins within 24-48 hours; clinical cure typically achieved after 3-day regimen. |
| Duration of Action | Local antimycotic effect persists for approximately 72 hours after last dose; complete eradication of Candida requires full 3-day course. |
| Molecular Weight | 344.84 |
Vaginal suppository: 200 mg at bedtime for 3 nights; topical cream (2%): apply intravaginally once daily for 3 nights.
| Dosage form | CREAM, TABLET |
| Renal impairment | No dosage adjustment required for any degree of renal impairment. |
| Liver impairment | No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to limited data. |
| Pediatric use | Adolescents (≥12 years): same as adult dosing (200 mg vaginal suppository at bedtime for 3 nights or 2% cream intravaginally once daily for 3 nights). Children <12 years: not recommended. |
| Geriatric use | Same as adult dosing; no specific adjustments required. |
| 1st trimester | Topical clotrimazole is generally considered safe in first trimester; systemic absorption minimal. Vaginal use is not recommended unless clearly needed. |
| 2nd trimester | Generally safe; vaginal use permitted when benefit outweighs risk. |
| 3rd trimester | Generally safe; no known fetal risk. |
Clinical note
Comprehensive clinical and safety monograph for GYNE-LOTRIMIN 3 COMBINATION PACK (GYNE-LOTRIMIN 3 COMBINATION PACK).
| Placental transfer | Minimal to none after topical/vaginal application; systemic absorption <1%. |
| Breastfeeding | Minimal systemic absorption after topical or vaginal administration; unlikely to be excreted into breast milk. Considered compatible with breastfeeding. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to clotrimazole or any componentOcular use
| Precautions | For intravaginal use only; not for oral or ophthalmic use, If no improvement in 3 days or symptoms persist >7 days, reevaluate diagnosis, Discontinue if hypersensitivity reactions occur, May cause vaginal irritation, burning, or cramping, Safety not established in pregnant women (Category C); use only if potential benefit outweighs risk, Do not use if abdominal pain, fever, or malodorous discharge present |
| Food/Dietary | No significant food interactions reported. Avoid excessive sugar intake as it may promote Candida growth. |
Loading safety data…
| Safe |
| Teratogenic Risk | Clotrimazole: Topical use not associated with increased risk of major birth defects; limited systemic absorption. Animal studies show no teratogenicity at doses up to 100 mg/kg. Vaginal administration has minimal absorption. Betamethasone: Corticosteroid; studies suggest slight increase in oral clefts with first trimester systemic use; risk with topical use is low due to low systemic absorption. Third trimester: Betamethasone may cause fetal adrenal suppression if used in high doses. Overall risk is low with combination pack as directed. |
| Fetal Monitoring | No routine monitoring required for clotrimazole. For betamethasone: Monitor maternal blood glucose, fetal growth if repeated high doses; assess for symptoms of Cushing's syndrome in neonate if prolonged exposure. |
| Fertility Effects | No known effects on fertility from clotrimazole or betamethasone topical/vaginal use. |
| Clinical Pearls |
| Gyne-Lotrimin 3 Combination Pack contains clotrimazole vaginal inserts (200 mg each for 3 nights) and external cream. For uncomplicated vulvovaginal candidiasis, a 3-day regimen is as effective as 7-day therapy. Advise patients to complete full course even if symptoms resolve. Caution in pregnancy: category C; use only if clearly needed. For recurrent infections, consider culture to confirm Candida species and rule out non-albicans species or resistance. Avoid concurrent use of condoms or diaphragms due to cream base weakening latex. If bleeding or lower abdominal pain occurs, evaluate for alternative diagnoses. |
| Patient Advice | Insert one vaginal tablet at bedtime for 3 consecutive nights. · Apply a thin layer of external cream to the vulvar area twice daily as needed. · Wash hands before and after application. · Continue treatment even if menses begins; do not use tampons during therapy. · Avoid sexual intercourse during treatment. · Do not use if allergic to clotrimazole or any ingredient. · Seek medical advice if symptoms persist after 3 days or recur within 2 months. · Pregnant women: consult healthcare provider before use. |